Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




DuPont to Acquire Verdia Subsidiary of Maxygen

By Biotechdaily staff writers
Posted on 09 Jun 2004
To enhance its research and discovery capabilities, DuPont (Wilmington, DE, USA) has agreed to acquire Verdia, Inc. More...
(Redwood City, CA, USA), a subsidiary of Maxygen, Inc. (also in Redwood City).

DuPont plans to purchase the plant sciences company for U.S.$64 million in cash. DuPont will have worldwide, royalty-free rights to use Maxygen's MolecularBreeding directed evolution platform, known as gene shuffling, for agricultural applications across its agriculture and nutrition platform. DuPont plans to retain Verdia's name.

Scientists at Verdia and another DuPont subsidiary, Pioneer Hi-Bred International, unveiled the first agricultural trait developed through gene shuffling in the May 21, 2004, issue of Science. Pioneer currently has this trait, glyphosate resistance, in field tests in corn and expects to have it on the market within the next five to six years. DuPont will be able to tap Verdia technology and expertise to improve plants' health benefits, nutritional value, and taste for the consumer market while also improving processing attributes for food manufacturers.

"Verdia will significantly enhance our gene research and trait discovery capabilities,” said Jim Miller, DuPont vice president, crop genetics research and development. "The technology should allow us to reach research targets up to three years faster and more efficiently.”




Related Links:
DuPont
Maxygen

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Gold Member
Hematology System
Medonic M16C
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.